📈 Why Emcure Pharmaceuticals recently gained momentum?

Emcure Pharmaceuticals has received CDSCO approval to market Poviztra for the treatment of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in adults with moderate to advanced liver fibrosis (F2–F3). This approval expands the use of innovator semaglutide, which is already prescribed for obesity, cardiovascular risk reduction, and adolescent obesity. The new indication strengthens Emcure's presence in the fast-growing metabolic disease segment while addressing a condition with limited treatment options. The positive regulatory development has boosted investor sentiment, contributing to the stock's recent upward move. 📊